EP4259141A4 - Compositions de favipiravir à charge médicamenteuse élevée - Google Patents

Compositions de favipiravir à charge médicamenteuse élevée

Info

Publication number
EP4259141A4
EP4259141A4 EP20965250.2A EP20965250A EP4259141A4 EP 4259141 A4 EP4259141 A4 EP 4259141A4 EP 20965250 A EP20965250 A EP 20965250A EP 4259141 A4 EP4259141 A4 EP 4259141A4
Authority
EP
European Patent Office
Prior art keywords
favipiravir
drug load
high drug
load compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20965250.2A
Other languages
German (de)
English (en)
Other versions
EP4259141A1 (fr
Inventor
Erol Kiresepi
Ersin Yildirim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santa Farma Ilac Sanayi AS
Original Assignee
Santa Farma Ilac Sanayi AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Farma Ilac Sanayi AS filed Critical Santa Farma Ilac Sanayi AS
Publication of EP4259141A1 publication Critical patent/EP4259141A1/fr
Publication of EP4259141A4 publication Critical patent/EP4259141A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20965250.2A 2020-12-08 2020-12-08 Compositions de favipiravir à charge médicamenteuse élevée Pending EP4259141A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2020/051259 WO2022125006A1 (fr) 2020-12-08 2020-12-08 Compositions de favipiravir à charge médicamenteuse élevée

Publications (2)

Publication Number Publication Date
EP4259141A1 EP4259141A1 (fr) 2023-10-18
EP4259141A4 true EP4259141A4 (fr) 2024-09-11

Family

ID=81974489

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20965250.2A Pending EP4259141A4 (fr) 2020-12-08 2020-12-08 Compositions de favipiravir à charge médicamenteuse élevée

Country Status (2)

Country Link
EP (1) EP4259141A4 (fr)
WO (1) WO2022125006A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010221A1 (en) * 2009-03-13 2012-01-12 Toyama Chemical Co.,Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
CN106667926A (zh) * 2015-11-09 2017-05-17 石药集团中奇制药技术（石家庄）有限公司 一种法匹拉韦片剂及其制备方法
WO2022115055A1 (fr) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Composition à libération immédiate de favipiravir

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2731932C1 (ru) * 2020-05-07 2020-09-09 Общество с ограниченной ответственностью "Кромис" (ООО "Кромис") Противо-COVID-19 (SARS-CoV-2) вирусная фармацевтическая композиция

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010221A1 (en) * 2009-03-13 2012-01-12 Toyama Chemical Co.,Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
CN106667926A (zh) * 2015-11-09 2017-05-17 石药集团中奇制药技术（石家庄）有限公司 一种法匹拉韦片剂及其制备方法
WO2022115055A1 (fr) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Composition à libération immédiate de favipiravir

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022125006A1 *

Also Published As

Publication number Publication date
EP4259141A1 (fr) 2023-10-18
WO2022125006A1 (fr) 2022-06-16

Similar Documents

Publication Publication Date Title
EP3914252A4 (fr) Composition pharmaceutique du nilotinib
IL292439A (en) Pharmaceutical preparations of albumin and rapamycin
GB202019241D0 (en) Pharmaceutical composition
GB202014160D0 (en) Senolytic compounds and compositions
IL289557A (en) Sustained release formulations of endoxifen
IL290324A (en) Preparations containing tropintide
IL304159A (en) A preparation containing bl-8040
EP4259141A4 (fr) Compositions de favipiravir à charge médicamenteuse élevée
IL300090A (en) Pharmaceutical preparations containing VENGLUSTAT
EP4175626A4 (fr) Nouvelles compositions pharmaceutiques
EP4230210A4 (fr) Composition pharmaceutique stable
IL307482B2 (en) Placement of hair coloring materials
EP4236923A4 (fr) Composé anti-vertige et compositions pharmaceutiques de celui-ci
IL286197A (en) Stable topical compositions of phenoldopam
EP4251153A4 (fr) Formulations lyophilisées de tegavivint
PT4153133T (pt) Composições farmacêuticas injetáveis e utilizações das mesmas
EP3714902C0 (fr) Stabilisation de compositions pharmaceutiques comprenant un polysorbate
IL312073A (en) Pharmaceutical preparations of aproxypramine
IL312071A (en) medicinal preparations
GB202019335D0 (en) Pharmaceutical compositions
GB202013701D0 (en) Pharmaceutical compositions
IL307928A (en) Pharmaceutical preparations containing picroside
GB202005742D0 (en) Novel pharmaceutical compositions
GB202313738D0 (en) Pharmaceutical compositions
GB202312055D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/16 20060101ALI20240807BHEP

Ipc: A61K 9/20 20060101ALI20240807BHEP

Ipc: A61K 31/4965 20060101AFI20240807BHEP